Hormone treatment vs chemotherapy before breast surgery
Part of Cancer, Skin clinical trials.
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 35 and 55 years old and considered premenopausal by the study team
- Your breast cancer is primary invasive breast cancer (not spread to other organs)
- Your tumor is hormone-receptor positive (ER or PR positive) and HER2 negative by testing
- You have not had any prior treatment for this breast cancer
- The cancer stage fits: T2N0M0 (tumor over 2 cm, lymph node biopsy negative, no distant spread) and breast-conserving surgery is difficult or could change the appearance
- You can safely receive the study treatments and surgery (no major heart/stroke issues, major liver/kidney/blood problems, or anesthesia/surgery contraindications)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies treatments given before surgery for invasive breast cancer, aiming to shrink the tumor so surgery can be done more effectively. It may help some people need breast-conserving surgery or improve the chance of complete cancer removal.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This study looks at how a hormone-blocking medicine (endocrine therapy) given before surgery affects a marker called Ki67 in your breast cancer cells. The goal is to see if the medicine can slow the growth of the cancer, which may help doctors choose the best treatment for you.
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.